logo
  

Intel Names Bruce H. Andrews As Corporate VP

Intel Corporation (INTC) on Thursday said it has appointed Bruce H. Andrews as corporate vice president and chief government affairs officer, effective September 7.

Intel said, Andrews, who is expected to report to Steven R. Rodgers, Intel's executive vice president and general counsel, will lead the company's global government affairs group and oversee the Intel's government affairs and public policy functions and strategies.

"Government affairs plays a heavy role in today's global and increasingly complex political landscape, and Bruce will help advance our collaboration with governments around the world as we address the soaring global need for semiconductors," said Pat Gelsinger, Intel's CEO.

Andrews joins intel from SoftBank Group, were he served as senior vice president and managing partner, co-leading global government affairs. He has worked as deputy secretary of the U.S. Department of Commerce and chief of staff to the secretary along with executive roles in other companies.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Privately-held biotechnology company On Target Laboratories, Inc. announce that the U.S. Food and Drug Administration or FDA, has approved Cytalux (pafolacianine) for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions. Cytalux is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively. The Federal Trade Commission or FTC has ordered Walmart, Amazon, Kroger and certain other large wholesalers and suppliers to provide information to help it study causes of supply chain disruptions. The agency has launched an inquiry to find the reasons for empty shelves and exorbitant prices. Along with Walmart, Amazon.com, and Kroger, the order has been sent to C&S Wholesale Grocers, Associated.. Covid vaccine maker Moderna Inc.'s Chief Executive Stéphane Bancel has predicted that existing COVID-19 vaccines will be much less effective against Omicron than earlier strains, according to the Financial Times.
Follow RTT